There is no doubt modern IT infrastructures are a critical component for pharmaceuticals companies to thrive in this competitive digital age. Without a flexible, agile infrastructure, they aren’t able to keep up with the different life sciences teams they support. They need a modernized IT ecosystem that allows for flexibility, lower administration and management costs, a smaller data center footprint, increased reliability, and much faster delivery time frames. In order to do so, many pharmaceutical companies are moving to the cloud for a more secure, scalable, and flexible infrastructure.
With the genomic data footprint of pharmaceutical companies being on a path of rapid growth, pharmaceutical companies are also turning to Converged Infrastructure (CI) to consolidate workloads and provide a simpler way to manage and serve up an internal private cloud or a hybrid cloud workload. CI allows pharmaceutical companies to fully utilize the cloud and emerging technologies such as advanced analytics and artificial intelligence in a faster more agile manner with a lower total cost of ownership.
In a recent interview with David Pelleman, Director of Sales at IronBrick, he said, “One of the challenges pharmaceutical companies face is the time it takes to bring a new drug to market. In some cases, it may take ten years or more, with only a small percentage of those drugs actually making it to the customer. It is imperative for research and development teams to look for ways to bring the next drug to market faster. We see more and more pharmaceutical companies turning to machine learning and artificial intelligence to address this challenge. Combining technologies such as NVIDIA GPUs with a Converged Infrastructure High Performance Computing Cluster (HPCC) platform increases time to delivery and parallel processing of workloads.”
According to the 2017 Pharmaceuticals and Life Sciences Industry Trends Report published by PricewaterhouseCoopers, more pharmaceutical companies today are adopting technologies to help determine the direction of product development, all with the hopes of getting the right products to market faster. They are also reexamining the way they look at the value of their products, pricing, and distribution structures and designing systems that will accelerate time to market and allow for more effective communication with patients to monitor outcomes.
While creating and managing a complex HPCC to help scientists handle, analyze and, share information presents challenges, some pharmaceutical companies are leading the pack to create the IT ecosystems needed to operate in this challenging environment.
Pelleman shared with us, “We are seeing success stories of companies that are dramatically improving server delivery times with a new Converged Infrastructure platform. Previously, virtual or physical server requests from a business were fulfilled in as many as 173 days. Now that same request is fulfilled in 3 hours due to a modernized IT ecosystem based on a Converged Infrastructure platform. At IronBrick, we take a holistic approach to building out a modernized IT ecosystem, one that scales and operates with a service model approach.”
That said, new and modernized IT ecosystems should not mean a more complex infrastructure. In fact, it means the opposite. Simplifying the data center, IT administration and management, is at the core of moving to a converged infrastructure platform.
Find out how IronBrick can transform your IT environment here.